Building a Compliant Drug Safety Framework for Early-Phase Clinical Trials
As biotech organizations advance promising therapies through clinical development, pharmacovigilance requirements become increasingly complex. Following the successful completion of Phase I clinical trials, a biotech company preparing for Phase II anticipated a significant increase in serious adverse event (SAE) reporting and associated drug safety workload. The organization required an experienced pharmacovigilance partner to establish a scalable, compliant framework capable of supporting future growth while minimizing internal resource demands.
Qinecsa worked closely with the client to develop and implement a robust drug safety operating model, combining pharmacovigilance services, safety database expertise, and regulatory intelligence to support ongoing clinical development.
The Challenge: Preparing for Increased SAE Volumes
Having successfully completed Phase I studies, the client was rapidly progressing into Phase II clinical trials. With this advancement came expectations of significantly increased SAE volumes and corresponding case processing requirements.
Limited Internal Resources
The anticipated workload could not be effectively managed in-house, creating the need for external pharmacovigilance support. The client required a partner with deep drug safety expertise who could proactively manage key safety activities while requiring minimal oversight from the sponsor’s internal team. Resource constraints made efficiency and operational independence essential components of the solution.
The Solution: A Scalable Pharmacovigilance Framework
Qinecsa collaborated with the client to establish the processes, systems, and expertise needed to support the next stage of clinical development. The engagement focused on creating a compliant and sustainable foundation for clinical safety operations.
Safety Database Selection
An appropriate safety database was selected in partnership with the client. The decision was driven by expectations associated with the compounds in scope and the anticipated growth in safety reporting requirements as development progressed.
Regulatory Intelligence and Global Readiness
Qinecsa proactively gathered regulatory intelligence for markets where clinical trials were expected to commence. This enabled the client to better prepare for global development activities and understand local reporting requirements before trial expansion.
Building Product Knowledge
As SAE volumes increased, a strong and continuously maintained knowledge base was developed around the compounds under investigation. This helped ensure safety information was reviewed consistently and supported informed decision-making throughout the clinical development program.
The Outcome: A Robust and Compliant Drug Safety Program
The client successfully established a compliant drug safety framework that met both budget and quality expectations while preparing the organization for increased reporting volumes.
The regulatory intelligence gathered for active markets enabled the client to proactively establish global partnerships to support submissions and follow-up activities. In addition, product knowledge was continually reviewed and evaluated through a structured process with clearly documented decisions and outcomes.